MacroGenics Director William Heiden Purchases Shares at ~$1.50

Rhea-AI Filing Summary

William K. Heiden, a director of MacroGenics, Inc. (MGNX), reported two open-market purchases of the company's common stock. On 08/19/2025 he purchased 50,500 shares at aggregate prices reported as $1.52 with trade prices in a range of $1.48 to $1.59, bringing his direct beneficial ownership to 61,500 shares. On 08/20/2025 he purchased an additional 49,500 shares at an aggregate price reported as $1.49 with trade prices in a range of $1.46 to $1.50, increasing his direct beneficial ownership to 111,000 shares. The Form 4 was signed by attorney-in-fact Beth A. Smith on 08/21/2025.

Positive

• Director executed open-market purchases of 50,500 and 49,500 shares on 08/19/2025 and 08/20/2025, respectively.
• Reporting provides price transparency with disclosed trade price ranges ($1.48–$1.59 and $1.46–$1.50) and reported aggregate prices ($1.52 and $1.49).
• Direct beneficial ownership increased to 111,000 shares after the reported transactions.
• Form 4 was timely and properly executed by an attorney-in-fact, indicating compliance with Section 16 reporting rules.

Negative

• None.

Insights

Financial Analyst

TL;DR Insider director purchases 100,000 total shares over two days, raising his direct stake to 111,000 shares.

From a trading-signals perspective, director purchases of common stock are typically viewed positively because they indicate personal capital deployment into the company. The Form 4 shows two separate purchase events executed in multiple trades with disclosed price ranges and reported average prices, which provides transparency on execution. The disclosed post-transaction direct ownership of 111,000 shares quantifies the director's stake but the filing does not provide context on percentage ownership or company share count, so the absolute impact on control or valuation cannot be assessed from this form alone.

Corporate Governance Expert

TL;DR A director executed open-market purchases and timely reported the transactions via Form 4.

Procedurally, the filing meets Section 16 disclosure requirements: it identifies the reporting person as a director, lists transaction dates, transaction codes, price ranges, and updated beneficial ownership. The use of an attorney-in-fact signature is documented. The filing contains no indications of planned dispositions, agreements, or unusual derivative activity. Without additional governance context or percentage ownership details, the transactions are routine insider purchases rather than governance-altering events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEIDEN WILLIAM K

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		P		50,500	A	$1.52(1)	61,500	D
Common Stock	08/20/2025		P		49,500	A	$1.49(2)	111,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.48 to $1.59. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

2. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.50. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did William K. Heiden report for MGNX?

Heiden reported two open-market purchases: 50,500 shares on 08/19/2025 and 49,500 shares on 08/20/2025.

How many shares does William K. Heiden beneficially own after these transactions?

Heiden's direct beneficial ownership increased to 111,000 shares following the reported purchases.

At what prices were the MGNX shares purchased according to the Form 4?

Trades were executed in ranges: $1.48 to $1.59 on 08/19/2025 (reported $1.52) and $1.46 to $1.50 on 08/20/2025 (reported $1.49).

Who signed the Form 4 for these MGNX transactions?

The form was signed by Beth A. Smith, attorney-in-fact, on 08/21/2025.

Does the Form 4 show any derivative transactions or dispositions by Heiden?

No. The filing lists only non-derivative acquisitions; Table II contains no derivative transactions.